Your impact
Investing in innovative and groundbreaking research to help change the future for brain cancer patients and their families.
Brain cancer is deadly. Survival rates are low.
Brain cancer kills more children in Australia than any other disease and more people under 40 than any other cancer.
We're here to change that.
The devastating reality of brain cancer
Only 22% of people diagnosed with brain cancer will survive five years post-diagnosis.
Brain cancer survival rates have have only increased by 2% in the last decade.
We strive to change these statistics by persistently investing in innovative and groundbreaking research. Through your support, we believe we can rapidly increase brain cancer survival and improve the quality of life for people living with this disease.
This ethos is at the core of everything we do.
A cure will only be made possible by investing in novel, impactful research.
More funding will allow researchers to learn more about brain tumours and turn pre-clinical ideas into powerful therapies ready for clinical trials.
Your support can make this happen.
What your support enables
Thanks to our amazing community of fundraisers, we are able to fund some of the most promising research projects and clinical trials in Australia.
$30.8 million
invested in Australian brain cancer research: $20 million adult-related and over $10 million child-related.
$11.43 million
invested in clinical trials, including $8 million in GBM AGILE, the world's first global "adaptive" clinical trial for brain cancer
80 Grants
awarded to researchers, including 8 grants through our Fellowship program.
$2.5 million
In funding provided for early and mid-career researchers through our Fellowship Program.
Meet some of our Research Fellows
We believe that to improve survival rates and quality of life for people affected by brain cancer, we must invest in the next generation of scientific leaders.
Our Early and Mid-Career Fellowships enable researchers to pursue bold ideas and drive the breakthroughs that could shift the trajectory of brain cancer.
Dr Susannah Hallal
Chris O'Brien Lifehouse
Investigating extracellular vesicle molecular signatures to enhance understanding of brain cancer biology and improve diagnostic and therapeutic strategies.
Dr Andrew Garvie
Exploring the potential of PMR-116, a novel RNA Polymerase I inhibitor, as a treatment for brain cancers with H3.3 and ATRX mutations.
Dr Hsiao Voon
Monash University
Targeting damaged PML bodies in paediatric gliomas using engineered models and patient samples to assess the efficacy of clinically approved drugs.
Dr Alex Davenport
WEHI
Developing innovative immunotherapies for paediatric brain cancer to advance treatment options for young patients.
#CBCFHero
Follow us on our socials for the latest news!
